Literature DB >> 14663290

Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease.

Carlos Gonzalez-Juanatey1, Javier Llorca, Ana Testa, Javier Revuelta, Carlos Garcia-Porrua, Miguel A Gonzalez-Gay.   

Abstract

We conducted the current study to search for subclinical atherosclerosis in patients with rheumatoid arthritis (RA) without clinically evident atherosclerosis or its complications who had been treated for a long duration, and to assess whether demographic or clinical factors affect the development of atherosclerotic disease. Forty-seven white patients fulfilling the 1987 American College of Rheumatology classification criteria for RA were recruited from Hospital Xeral-Calde, Lugo, Spain. Patients were required to have been treated for at least 5 years, including current treatment with 1 or more disease-modifying antirheumatic drugs. Patients with diabetes mellitus, renal insufficiency, hypertension, cardiovascular or cerebrovascular disease, and smokers were excluded. Forty-seven matched controls were also studied. Carotid intima-media wall thickness (IMT) and carotid plaques were measured in the right common carotid artery. The study was performed using high-resolution B-mode ultrasound. Patients had greater carotid IMT (0.779 +/- 0.164 mm) than did controls (0.699 +/- 0.129 mm); (p = 0.010). Sixteen (34%) patients showed carotid plaques compared with only 7 (15%) controls (p = 0.031). There was a positive correlation between the age at the time of study and the carotid IMT. Patients with carotid plaques had significantly greater carotid IMT (0.859 +/- 0.116 mm) than those without plaques (0.739 +/- 0.171 mm) (p = 0.014). Also, RA patients with carotid plaques had a significantly longer disease duration (mean, 21.0 yr) and more extraarticular manifestations (63%) than those without plaques (mean, 12.7 yr and 26%, respectively). Age at the time of the study and disease duration were the best predictive factors for the development of severe morphologic expression of atherosclerotic disease. The present study confirms an increased frequency of severe subclinical atherosclerotic findings in long-term actively treated RA patients from northwest Spain.

Entities:  

Mesh:

Year:  2003        PMID: 14663290     DOI: 10.1097/01.md.0000101572.76273.60

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  66 in total

1.  Accelerated atherosclerosis in patients with Wegener's granulomatosis.

Authors:  K de Leeuw; J-S Sanders; C Stegeman; A Smit; C G Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2004-09-16       Impact factor: 19.103

2.  Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors.

Authors:  Leonel Daza; Martin Aguirre; Martin Jimenez; Rafael Herrera; J J Bollain
Journal:  Clin Rheumatol       Date:  2006-06-07       Impact factor: 2.980

3.  Atherosclerosis in Systemic Sclerosis: a Modern Controversy.

Authors:  Stefania L Magda; Raluca I Mincu; Carmen M Mihai; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2015-09

Review 4.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

Review 5.  The unique features of vasculitis in Behçet's syndrome.

Authors:  Melike Melikoglu; Emire Kural-Seyahi; Koray Tascilar; Hasan Yazici
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

6.  Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis.

Authors:  Aysegul Kucukali Turkyilmaz; Gul Devrimsel; Aynur Kirbas; Yuksel Cicek; Murat Karkucak; Erhan Capkin; Ferhat Gokmen
Journal:  Rheumatol Int       Date:  2013-06-25       Impact factor: 2.631

Review 7.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis.

Authors:  Dragana Dragoljevic; Michael J Kraakman; Prabhakara R Nagareddy; Devi Ngo; Waled Shihata; Helene L Kammoun; Alexandra Whillas; Man Kit Sam Lee; Annas Al-Sharea; Gerard Pernes; Michelle C Flynn; Graeme I Lancaster; Mark A Febbraio; Jaye Chin-Dusting; Beatriz Y Hanaoka; Ian P Wicks; Andrew J Murphy
Journal:  Eur Heart J       Date:  2018-06-14       Impact factor: 29.983

Review 9.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

10.  Increased carotid intima-media thickness in rheumatoid arthritis: an update meta-analysis.

Authors:  Peng Wang; Shi-Yang Guan; Shu-Zhen Xu; Hong-Miao Li; Rui-Xue Leng; Xiang-Pei Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2015-11-27       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.